Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 3, 2026Genomics Proteomics & BioinformaticsOpen Access

Bispecific Antibodies in Cancer Immunotherapy: Mechanisms, Challenges, and Emerging Therapeutic Strategies

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYao WuMLMingjie LiaoHCHan Chen

Discussion

Loading...

Member takes

Overview

Review dissects applications of bispecific antibodies in immunotherapy, highlighting mechanisms and challenges.

Key Points

  • This review analyzes the applications of bispecific antibodies in cancer immunotherapy and evaluates their therapeutic potential and challenges.
  • Systematic review of existing bispecific antibody modalities
  • Evaluation of immune-related adverse events and drug resistance
  • Comparative mechanistic analysis of therapeutic efficacy and systemic toxicity
  • Bispecific antibodies show promise in enhancing cytotoxic activity against tumors, particularly with immune cell engagers.
  • Challenges include heterogeneous therapeutic responses and immune-related adverse events that affect clinical outcomes.
  • Emerging strategies like trispecific antibodies and proteolysis-targeting chimeras aim to enhance efficacy while reducing off-target toxicity.

Cite This Study

Wu et al. (2026) studied this question.

synapsesocial.com/papers/6a70406d75942ff7265e5705https://doi.org/10.1093/gpbjnl/qzag075
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Bispecific antibodies: current advances and future perspectives2026
  2. 2Bispecific antibodies: unleashing a new era in oncology treatment2025 · 40 citations
  3. 3Advances in the clinical application of bispecific antibodies in cancer therapy2025 · 8 citations
  4. 4Double hit — bispecific antibodies in cancer therapy2024
  5. 5Bispecific and multispecific immune engagers for redirecting innate and adaptive immunity against hematologic cancers2026